Recent News

• 03.11.2025 - CEO Message
• 03.04.2025 - Cumberland Pharmaceuticals 2024 Q4 earnings call
• 03.04.2025 - Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
• 02.25.2025 - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
• 02.18.2025 - VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
• 02.04.2025 - Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Recent Filings

• 03.10.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.10.2025 - DEF 14A Other definitive proxy statements
• 03.07.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.04.2025 - EX-99.1 EX-99.1
• 03.04.2025 - 8-K Current report
• 02.19.2025 - 8-K Current report
• 02.19.2025 - EX-99.1 EX-99.1
• 02.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.14.2025 - 8-K Current report
• 02.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors